ViiV Healthcare Receives FDA Approval of HIV Drug Tivicay - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ViiV Healthcare Receives FDA Approval of HIV Drug Tivicay



ViiV Healthcare, a specialist HIV company of GlaxoSmithKline (GSK), Pfizer, and Shionogi, has received FDA approval for Tivicay (dolutegravir) 50-mg tablets. Tivicay is an integrase inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 in adults and children aged 12-years and older weighing at least 40 kg (approx. 88 lbs).

ViiV Healthcare was established in November 2009 by GlaxoSmithKline and Pfizer to focus on developing treatments for HIV. The Japanese pharmaceutical company Shionogi joined as a 10% shareholder in October 2012 following a long-term collaboration on the joint development of several integrate inhibitors. ViiV Healthcare has a current portfolio of 11 HIV treatments, which generated 2012 sales of £1.4 billion ($2.2 billion). 

Tivicay is the first new treatment delivered by ViiV Healthcare. ViiV Healthcare also submitted a marketing authorization application for dolutegravir to the EMA in December 2012. Regulatory applications are also being evaluated in other markets worldwide, including Canada, Australia, and Brazil. Submission of regulatory files to support a fixed-dose combination of Tivicay and abacavir/lamivudine is anticipated in 2013.

Source: GlaxoSmithKline

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here